Haisco Pharmaceutical Group News

Southwest Securities released a research report on April 24 stating that it gave HiCisco (002653.SZ) a purchase rating. The main reasons for the rating include: 1) the domestic market share of cyclopofol is 11%, and it is expected that NDA will be declare

Zhitong FinanceApr 24 16:24

Debon Securities released a research report on April 23 stating that it gave HiCisco (002653.SZ) a purchase rating. The main reasons for the rating include: 1) the performance was in line with expectations, and Q1 revenue increased 20% year over year; 2)

Zhitong FinanceApr 23 08:55

HiCisco (002653): The differentiated innovative layout has entered the harvest period, and the pipeline is rich and has great potential

德邦證券Apr 22 19:02

HiCisco (002653): Performance is in line with expectations, new product launches are progressing steadily

華西證券Apr 22 00:00

HiCisco (002653): HSK16149 approved, can be expected to go overseas

西南證券Apr 21 00:00

Hisilico (002653): Q3 performance exceeded expectations, HSK21542 listing application accepted

西南證券Oct 30, 2023 00:00

Hisco (002653): Cyclopofol continues to be realized, R&D innovation is gradually being reaped

東吳證券Aug 21, 2023 15:03

HiCisco (002653): Performance growth is in line with expectations, continuous investment in innovative drug development

華西證券Aug 18, 2023 20:47

Hisco (002653): Rapid deployment of innovative products, rapid advancement of R&D pipeline

國海證券Aug 17, 2023 14:17

Hisco (002653): Rapid release of cyclopofol, many new drugs have been declared NDA

西南證券Aug 16, 2023 00:00

Hisco (002653): Performance continues to improve, pipeline battery life is strong

中信建投證券Apr 30, 2023 00:00

Hisco (002653): Performance is in line with expectations for rapid release of cycloprolol

華西證券Apr 24, 2023 00:00

HISCO (002653) 2022 Report Review: Cycloprolol Continues to Grow Internationalized+BD Is Expected to Make a Breakthrough

東吳證券Apr 19, 2023 00:00

Hisco (002653): Revenue slightly exceeded expectations, and operations improved significantly year-on-year

東吳證券Oct 28, 2022 00:00

Hisco (002653): Significant improvement in performance and anticipation of cycloprolol going overseas

華西證券Oct 26, 2022 00:00

Hisco (002653): Cyclopropyl continues to deliver on the company's development and enters a new journey

東吳證券Aug 19, 2022 00:00

Hisco (002653): Performance inflection point has reached rapid release of cycloprolol

華西證券Aug 17, 2022 00:00

Hisco (002653): Cyclopropyl sales exceed expectations, innovation and transformation results are beginning to appear

中泰證券Aug 16, 2022 00:00

Hesco (002653): stock varieties short-term disturbance cyclopropofol accelerated release trend is clear

中泰證券Apr 28, 2022 00:00

Hisco (002653): Performance inflection points confirm that innovative drugs drive the second growth curve

中泰證券Apr 27, 2022 00:00